COM701 IN COMBINATION WITH NIVOLUMAB DEMONSTRATES PRELIMINARY ANTITUMOR ACTIVITY IN PATIENTS WITH PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER. (NCT03667716)

**BACKGROUND**

**COM701 is a novel, 2-into-cis-18 β-thiazolo[3,2-a]pyridine derivative that binds to PVRIG and acts as a non-canonical PD-L1 inhibitor.**

**Key Inclusion Criteria:**
- Patients with recalcitrant, high-grade serous adenocarcinoma, clear cell, or mixed histology ovarian cancers.
- Patients who have failed platinum-based chemotherapy.
- Patients with no other available systemic therapy options.
- Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0-1.

**Methods:**
- All patients received COM701 2.5 mg/kg in combination with nivolumab 3 mg/kg.
- Safety and tolerability were evaluated in patients with advanced ovarian cancer.

**Eligibility Criteria and Objectives**

**Key Inclusion Criteria:**
- Histologically confirmed locally advanced or metastatic high-grade serous epithelial ovarian cancer.
- Patients who have received prior chemotherapy including platinum.
- Patients with ECOG performance status 0-1.

**Key Exclusion Criteria:**
- Patients with a history of other malignancies.
- Patients with central nervous system metastases.
- Patients with uncontrolled hypertension or uncontrolled diabetes.

**Patient Disposition Summary**

**Characteristics**

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Histology</th>
<th>Ongoing study</th>
<th>n [ % ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>High grade serous adenocarcinoma</td>
<td>Yes</td>
<td>50 (10)</td>
</tr>
</tbody>
</table>

**Incidence of TRAEs (10% of Patients)**

<table>
<thead>
<tr>
<th>TRAE</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 5</th>
<th>All Grades</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>-</td>
<td>-</td>
<td>2 (10)</td>
<td>-</td>
<td>-</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (10)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Aspartate Aminotransferase Increased</td>
<td>-</td>
<td>-</td>
<td>2 (10)</td>
<td>-</td>
<td>-</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>-</td>
<td>2 (10)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Grade 3 proteinuria assessed by the PI as related to study drugs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Incidence of Related Serious Adverse Events - All Patients**

<table>
<thead>
<tr>
<th>TRAE</th>
<th>n</th>
<th>[ % ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>G3 Disease progression</td>
<td>11</td>
<td>55</td>
</tr>
<tr>
<td>G3 Any TRAE</td>
<td>9</td>
<td>45</td>
</tr>
</tbody>
</table>

**SUMMARY OF TREATMENT RELATED ADVERSE EVENTS**

**DISCLOSURES**

- Danae Hudson, Amanda Harp, Compugen USA Inc for clinical operations oversight of the study.
- Fleming GF et al. COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with platinum-resistant ovarian cancer. (NCT03667716). In: Proceedings of the Clinical Research, The START Center for Cancer Care, San Antonio, TX; USA, 6Department of Medicine, Division of Hematology - Medical Oncology, UCLA - David Geffen School of Medicine, Los Angeles; CA, USA, Clinical Development., Compugen USA Inc., San Francisco, CA, USA. 7, B. Izar10, A. Adewoye11, G. Cojocaru12, E. Ophir13, P. Ferre14, I. Barbiro14, E. Dumbrava15. 

**CONCLUSION**

COM701 in combination with nivolumab showed an inferior survival benefit in patients with platinum-resistant ovarian cancer, as compared with nivolumab alone. Further studies are needed to better understand the role of COM701 in this setting.

**REFERENCES**

- Vaena, DA, et al. Preclinical Research, Compugen Ltd., Holon, Israel, 9Drug Development, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; USA, 10Clinical Research, The START Center for Cancer Care, San Antonio, TX; USA, 11Department of Gynecologic Oncology, MGH - Massachusetts General Hospital, Boston, MA, USA, 12Medical Oncology, Columbia University Medical Center, New York, NY; USA. 13Clinical Development., Compugen USA Inc., San Francisco, CA, USA, 14Walling Compagnie., Holon, Israel, 15Research and Drug Discovery, Compagnie Ltd., Holon, Israel, 16Practical Research, Compagnie Ltd., Holon, Israel, 17The University of Texas MD Anderson Cancer Center, Houston, TX; USA.